Table 1 Patient characteristics (n = 526).
Characteristic | No. patients | % patients | Mean (± SD) |
|---|---|---|---|
Age (years) | 526 | 66.2 (range 27–91) | |
Sex | |||
Male | 336 | 64 | |
Female | 190 | 36 | |
Histological type | |||
Adenocarcinoma | 360 | 69 | |
Squamous cell carcinoma | 123 | 23 | |
Other | 43 | 8 | |
History of smoking | |||
No | 170 | 32 | |
Yes | 319 | 61 | |
Unknown | 37 | 7 | |
ECOG performance status | |||
0–1 | 321 | 61 | |
2–4 | 191 | 36 | |
Unknown | 14 | 3 | |
Concurrent interstitial pneumonitis | |||
No | 500 | 95 | |
Yes | 26 | 5 | |
Concurrent pulmonary emphysema | |||
No | 447 | 85 | |
Yes | 77 | 15 | |
Unknown | 2 | <1 | |
History of pulmonary tuberculosis | |||
No | 491 | 93 | |
Yes | 34 | 7 | |
Unknown | 1 | <1 | |
Prior surgery for lung cancer | |||
No | 337 | 64 | |
Yes | 189 | 36 | |
Prior chemotherapy for lung cancer | |||
No | 115 | 22 | |
Yes | 411 | 78 | |
Prior thoracic radiotherapy for primary lung cancer | |||
No | 330 | 63 | |
Yes | 194 | 37 | |
Unknown | 2 | <1 | |
Concurrent chemotherapy with agent other than gefitinib | |||
No | 485 | 92 | |
Yes | 41 | 8 | |
Thoracic radiotherapy concurrent with or after gefitinib treatment | |||
No | 478 | 91 | |
Yes | 48 | 9 | |
Absolute neutrophil count (/μL) | 485 | 4786 (± 3331) | |
Eosinophil count (/μL) | 483 | 163 (± 181) | |
Creatinine level (mg/dL) | 496 | 0.77 (± 0.44) | |
Platelet count (×104/μL) | 515 | 25.8 (± 10.3) | |
Albumin level (g/dL) | 424 | 3.67 (± 0.58) | |
Aspartate aminotransferase level (IU/L) | 487 | 25 (± 20) | |
Alanine aminotransferase level (IU/L) | 515 | 23 (± 25) | |
Lactate dehydrogenase level (IU/L) | 495 | 279 (± 318) |